Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more
Kamada (KMDA) - Net Assets
Latest net assets as of December 2025: $269.13 Million USD
Based on the latest financial reports, Kamada (KMDA) has net assets worth $269.13 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($378.79 Million) and total liabilities ($109.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $269.13 Million |
| % of Total Assets | 71.05% |
| Annual Growth Rate | 19.71% |
| 5-Year Change | 52.2% |
| 10-Year Change | 303.23% |
| Growth Volatility | 58.63 |
Kamada - Net Assets Trend (2008–2025)
This chart illustrates how Kamada's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kamada (2008–2025)
The table below shows the annual net assets of Kamada from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $269.13 Million | +3.72% |
| 2024-12-31 | $259.46 Million | +6.33% |
| 2023-12-31 | $244.02 Million | +38.63% |
| 2022-12-31 | $176.02 Million | -0.45% |
| 2021-12-31 | $176.82 Million | -1.02% |
| 2020-12-31 | $178.64 Million | +32.01% |
| 2019-12-31 | $135.32 Million | +20.42% |
| 2018-12-31 | $112.38 Million | +25.57% |
| 2017-12-31 | $89.49 Million | +34.08% |
| 2016-12-31 | $66.74 Million | -7.95% |
| 2015-12-31 | $72.51 Million | -10.48% |
| 2014-12-31 | $80.99 Million | -9.98% |
| 2013-12-31 | $89.97 Million | +216.87% |
| 2012-12-31 | $28.39 Million | +25.22% |
| 2011-12-31 | $22.67 Million | -14.39% |
| 2010-12-31 | $26.49 Million | -12.15% |
| 2009-12-31 | $30.15 Million | +138.48% |
| 2008-12-31 | $12.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kamada's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3252191049.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.08 Million | 5.60% |
| Other Comprehensive Income | $2.78 Million | 1.03% |
| Other Components | $268.34 Million | 99.71% |
| Total Equity | $269.13 Million | 100.00% |
Kamada Competitors by Market Cap
The table below lists competitors of Kamada ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veedol Corporation Limited
NSE:VEEDOL
|
$85.70 Million |
|
Bellevue Group AG
SW:BBN
|
$85.72 Million |
|
Fleetwood Ltd
AU:FWD
|
$85.72 Million |
|
PDS Limited
NSE:PDSL
|
$85.72 Million |
|
BGF Retail Co Ltd
KO:027410
|
$85.64 Million |
|
Dongwon System
KO:014820
|
$85.64 Million |
|
Aurelius Technologies Bhd
KLSE:5302
|
$85.61 Million |
|
Adcock Ingram Holdings Limited
PINK:AIHLF
|
$85.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kamada's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 259,464,000 to 269,125,857, a change of 9,661,857 (3.7%).
- Net income of 21,863,744 contributed positively to equity growth.
- Dividend payments of 12,485,217 reduced retained earnings.
- Other comprehensive income increased equity by 5,858,577.
- Other factors decreased equity by 5,575,247.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $21.86 Million | +8.12% |
| Dividends Paid | $12.49 Million | -4.64% |
| Other Comprehensive Income | $5.86 Million | +2.18% |
| Other Changes | $-5.58 Million | -2.07% |
| Total Change | $- | 3.72% |
Book Value vs Market Value Analysis
This analysis compares Kamada's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.28x to 1.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.96 | $8.89 | x |
| 2009-12-31 | $1.20 | $8.89 | x |
| 2010-12-31 | $1.06 | $8.89 | x |
| 2011-12-31 | $0.82 | $8.89 | x |
| 2012-12-31 | $0.99 | $8.89 | x |
| 2013-12-31 | $2.69 | $8.89 | x |
| 2014-12-31 | $2.25 | $8.89 | x |
| 2015-12-31 | $2.00 | $8.89 | x |
| 2016-12-31 | $1.83 | $8.89 | x |
| 2017-12-31 | $2.35 | $8.89 | x |
| 2018-12-31 | $2.77 | $8.89 | x |
| 2019-12-31 | $3.33 | $8.89 | x |
| 2020-12-31 | $4.01 | $8.89 | x |
| 2021-12-31 | $3.95 | $8.89 | x |
| 2022-12-31 | $3.93 | $8.89 | x |
| 2023-12-31 | $4.55 | $8.89 | x |
| 2024-12-31 | $4.49 | $8.89 | x |
| 2025-12-31 | $4.61 | $8.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kamada utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.12%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.19%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.41x
- Recent ROE (8.12%) is above the historical average (-12.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -98.45% | -81.81% | 0.36x | 3.33x | $-13.71 Million |
| 2009 | -73.08% | -147.09% | 0.24x | 2.09x | $-25.05 Million |
| 2010 | -57.29% | -41.83% | 0.40x | 3.46x | $-17.82 Million |
| 2011 | -15.40% | -6.25% | 0.65x | 3.77x | $-5.76 Million |
| 2012 | 0.92% | 0.36% | 0.82x | 3.14x | $-2.58 Million |
| 2013 | 0.49% | 0.63% | 0.51x | 1.55x | $-8.55 Million |
| 2014 | -15.60% | -17.57% | 0.60x | 1.48x | $-20.74 Million |
| 2015 | -15.54% | -16.07% | 0.69x | 1.41x | $-18.52 Million |
| 2016 | -10.09% | -8.69% | 0.78x | 1.49x | $-13.41 Million |
| 2017 | 7.71% | 6.71% | 0.84x | 1.36x | $-2.05 Million |
| 2018 | 19.84% | 19.48% | 0.83x | 1.23x | $11.06 Million |
| 2019 | 16.44% | 17.49% | 0.73x | 1.28x | $8.72 Million |
| 2020 | 9.59% | 12.86% | 0.63x | 1.18x | $-723.80K |
| 2021 | -1.26% | -2.15% | 0.33x | 1.80x | $-19.91 Million |
| 2022 | -1.32% | -1.79% | 0.40x | 1.83x | $-19.92 Million |
| 2023 | 3.39% | 5.81% | 0.40x | 1.45x | $-16.12 Million |
| 2024 | 5.57% | 8.99% | 0.43x | 1.43x | $-11.48 Million |
| 2025 | 8.12% | 11.19% | 0.52x | 1.41x | $-5.05 Million |
Industry Comparison
This section compares Kamada's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kamada (KMDA) | $269.13 Million | -98.45% | 0.41x | $85.65 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |